Navigation Links
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
Date:3/31/2008

TUCSON, Ariz., March 31 /PRNewswire/ -- ImaRx Therapeutics, Inc., a biopharmaceutical company developing and commercializing therapies for vascular disorders, today provided a corporate update along with fourth quarter and full year 2007 financial results.

2007 Year in Review:

-- Initiated TUCSON Phase I/II clinical study

-- Received FDA approval to market urokinase under new trade name

Kinlytic(TM)

-- Signed strategic licensing agreement with Bracco International

-- Completed Initial Public Offering

-- Awarded Phase I STTR grant from the National Institutes of Health

-- Signed research collaboration with Royal Philips Electronics

-- Extended expiration dating of urokinase product inventory

Key Corporate Highlights:

PhaseI/II TUCSON Clinical Trial and SonoLysis Program Update

In January of 2007, the Company initiated its TUCSON trial, a Phase I/II clinical study designed to assess the safety of the Company's proprietary MRX- 801 microbubbles in combination with ultrasound and tPA in ischemic stroke patients. The TUCSON trial was designed with four 18-patient cohorts to evaluate increasing doses of MRX-801. In the second dose cohort, the Company observed a greater number of reported symptomatic intracranial hemorrhages in subjects receiving treatment relative to controls and after consultation with the Data and Safety Monitoring Board elected to stop enrollment of the study.

Bradford A. Zakes, President and CEO stated, "Although we would have preferred to obtain more efficacy and safety data at higher doses of microbubbles, we were encouraged by the data from the first cohort of patients. One vial of MRX-801 in combination with ultrasound and tPA did not result in any reported cases of intracranial hemorrhage in the treatment group, suggesting a safe dose for further clinical studies. Furthermore, an analysis of activity from the first cohort indicated a trend
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
2. ImaRx to Report Corporate Updates and 4Q07 Financial Results
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
5. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
6. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
7. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
8. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
9. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
10. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
11. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Franklin, MA (PRWEB) September 17, 2014 ... pre-engineered version of its TerraPure tank . This ... tanks is molded from FDA-compliant linear polyethylene and available ... seven pre-installed fittings and ships in two weeks or ... same features and benefits found in Terracon’s existing TerraPure ...
(Date:9/17/2014)... SAN FRANCISCO, Calif. , Sept. 17, 2014 /PRNewswire/ ... ), a molecular diagnostics company pioneering the field of ... Hall to chief operating officer. Mr. Hall ... spearhead the company,s commercial entry into endocrinology. Since 2012, ... operations, as well as managed care and billing functions. ...
(Date:9/17/2014)... 17, 2014 First ... from a truly novel class of anti-infective ... Biopharma, a biopharmaceutical company developing a truly ... it has secured £4.0m ($6.4m) to advance ... against a range of Gram-positive infections including  ...
(Date:9/16/2014)... Sept. 16, 2014 This report analyzes the worldwide ... Segments: Software, Hardware, and Biocontent. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts are provided ... analysis is provided for these markets. Market data and analytics ...
Breaking Biology Technology:Terracon Introduces Pre-Engineered TerraPure® Tank for Ultrapure Water Applications 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 2Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 3Veracyte, Inc. Announces Promotion of Christopher M. Hall To Chief Operating Officer 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23
... Allows Accurate Marketing Claims Designed with Input from,Entire ... nation,s leading livestock,cloning companies announced today a tracking ... allow food companies to identify cloned animals,when they ... program was developed through extensive cooperative discussions,over the ...
... MATEO, Calif., Dec. 19 BioForm Medical,Inc. (Nasdaq: ... will present a company overview at the upcoming 26th ... BioForm,Medical,s presentation will take place on Monday, January 7th, ... Westin St. Francis Hotel in San Francisco,CA., A ...
... Holdings, Inc. (OTC,Bulletin Board: HTWO) announced today that ... Mirant Energy Trading LLC, a subsidiary of Mirant ... biofuel technology in utility,scale power generation applications., ... biofuel for a gas,turbine test program that will ...
Cached Biology Technology:Top U.S. Cloning Companies Announce New System to Track Cloned Livestock 2BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008 2H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp. 2H2Diesel Holdings Announces Test Burn Agreement With Mirant Corp. 3
(Date:9/17/2014)... plastic shopping bags and their environmental impact recently scored ... first statewide ban on the bags, and Governor Jerry ... bag industry is not yielding without a fight, according ... , the weekly newsmagazine of the American Chemical Society. ... that the anti-bag campaign logged its first small victory ...
(Date:9/17/2014)... have obtained the first partial genome sequence of an ... at the site of the Montsoriu Castle in Girona, ... closely related to today,s Iberian pig. Researchers also discard ... Iberian pigs. , The study, published in Heredity ... species, and particularly on that of the Iberian breed, ...
(Date:9/17/2014)... Researchers at UTSouthwestern Medical Center have found that the ... called apoE3, helps repair the lining of blood vessels. ... the benefit of this repair, putting them at higher ... have identified one mechanism by which apoE3 promotes a ... is detrimental," said Dr. Philip Shaul , Professor ...
Breaking Biology News(10 mins):Iberian pig genome remains unchanged after 5 centuries 2Protein variant may boost cardiovascular risk by hindering blood vessel repair 2
... Medicine and University of Crete School of Medicine researchers ... a molecular mechanism that dynamically alters the strength of ... the development of drug therapies for the cognitive deficits ... bipolar disorder, or attention deficit hyperactivity disorder (ADHD). ...
... novel gene mutation that causes X-linked mental retardation for ... to an article to be published electronically on Tuesday, ... Genetics. , Investigators F. Lucy Raymond (Cambridge Institute ... Patrick S. Tarpey (Wellcome Trust Sanger Institute, Hixton, UK) ...
... the University of California, San Diego and the University ... of estimated plant species richness. Covering several hundred thousand ... most extensive map of the distribution of biodiversity on ... study published in this week's early online issue of ...
Cached Biology News:Brain networks strengthened by closing ion channels 2Brain networks strengthened by closing ion channels 3Severe mental retardation gene mutation identified 2Biologists produce global map of plant biodiversity 2
Request Info...
Limit of detection: <5 pg/ml...
Request Info...
... the premium quality siRNAs you need for ... be readily ordered online by providing either ... providing the sense and antisense siRNA sequences. ... Silencer Pre-designed siRNAs, which are already designed ...
Biology Products: